Core Viewpoint - Quanex Building Products Corporation is facing a class action lawsuit due to significant operational issues in its Tyman facility in Mexico, which have adversely affected its financial performance and misled investors about the company's operational health [1][4]. Financial Performance - For Q3 2025, Quanex reported a diluted EPS of ($6.04), a significant decline from $0.77 in the same period the previous year [2]. - The adjusted EBITDA for the same quarter was reported at $70.30 million [2]. - The operational challenges in the Tyman facility negatively impacted EBITDA in the Hardware Solutions segment by almost $5 million during Q3 2025 [3]. Stock Market Reaction - Following the announcement of the financial results, Quanex's stock price fell by $2.73, or 13.1%, closing at $18.18 per share on September 5, 2025 [3]. - The stock continued to decline, dropping an additional $1.98, or 10.9%, to close at $16.20 per share on September 8, 2025 [3]. Lawsuit Details - The class action lawsuit alleges that the company made materially false and misleading statements regarding its business operations and failed to disclose significant operational issues in the Tyman facility [4]. - Specific allegations include underinvestment in tooling and equipment maintenance, leading to degraded conditions and increased costs, which were not communicated to investors [4]. Legal Action Timeline - Investors who purchased Quanex securities during the class period (December 12, 2024, to September 5, 2025) have until November 18, 2025, to file a lead plaintiff motion in the class action lawsuit [1][5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Spectrum Pharmaceuticals, Inc. during the specified class period of the upcoming lead plaintiff deadline on September 24, 2025 [1]. Group 1: Class Action Details - Investors who bought Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][5]. - The lawsuit alleges that Spectrum made false or misleading statements regarding its PINNACLE Study related to the drug poziotinib, which impacted investors when the true details were revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Class Certification Status - No class has been certified yet, meaning investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [6].

Core Viewpoint - A lawsuit has been filed against Charter Communications, Inc. and certain senior executives for potential violations of federal securities laws, particularly related to the impact of the Affordable Connectivity Program's termination on the company's customer base and earnings [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Sandoval v. Charter Communications, Inc., No. 1:25-cv-06747, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until October 14, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Charter is a leading broadband and cable operator that participated in the FCC's Affordable Connectivity Program (ACP), which provided funding to subsidize high-speed internet plans for low-income households [3]. - The ACP ended in June 2024 due to a lack of federal funding, leading to customer declines for Charter [3]. Group 3: Financial Impact - During the relevant period, Charter claimed to have successfully managed the risks associated with the end of the ACP, stating that the impact was behind them [4]. - However, the company continued to experience declines in internet customers and revenue due to the program's termination [4]. - In Q2 2025, Charter reported a decrease of 117,000 total internet customers, including approximately 50,000 disconnects related to the ACP's end, nearly double the disconnects from the previous quarter [5]. - Following this announcement, Charter's stock price fell by $70.25 per share, or 18.4%, from $380.00 on July 24, 2025, to $309.75 on July 25, 2025 [5].

Core Viewpoint - Replimune Group, Inc. is facing a securities fraud lawsuit following significant stock price declines due to regulatory setbacks and alleged misleading statements regarding its clinical trials [1][3]. Group 1: Stock Performance and Regulatory Issues - Replimune's stock plummeted over 70% on July 22 after receiving a Complete Response Letter (CRL) from the FDA, which rejected its application for an advanced melanoma therapy due to insufficient clinical evidence from a Phase 2 study [2]. - The stock experienced another decline of over 40% on September 18 after a Type A meeting with the FDA, leaving the path forward under the accelerated approval pathway uncertain [2]. Group 2: Legal Actions and Investor Eligibility - A complaint has been filed against Replimune, alleging that the company made materially false and misleading statements about its IGNYTE clinical trial and the prospects for regulatory approval of its treatment [3]. - Investors who purchased Replimune common stock between November 22, 2024, and July 21, 2025, and have experienced losses may be eligible to participate in the lawsuit [4]. Group 3: Next Steps for Investors - The deadline for investors to seek appointment as lead plaintiff is September 22, 2025, and a class has not yet been certified [5]. - Investors are encouraged to contact Block & Leviton for more information on how to proceed if they have lost money on their investment [5]. Group 4: Whistleblower Information - Individuals with non-public information about Replimune are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 5: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - PubMatic, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its business operations and a significant reduction in ad spend from a top demand-side platform (DSP) partner, which negatively impacted its stock price [2][3]. Group 1: Company Financial Performance - On August 11, 2025, PubMatic released its Q2 2025 financial report, revealing a reduction in ad spend from one of its top DSP partners [2]. - The stock price of PubMatic fell by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025, following the financial report [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that during the Class Period, PubMatic's executives made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include the failure to disclose the shift of clients to a new platform by a top DSP buyer, resulting in reduced ad spend and revenue for PubMatic [3]. Group 3: Legal Actions - Investors who purchased PubMatic securities during the Class Period can file a lead plaintiff motion by October 20, 2025, to participate in the class action lawsuit [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Petco Health and Wellness Company, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 29, 2025 [1]. Group 1: Class Action Details - Investors who bought Petco securities between January 14, 2021, and June 5, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the August 29, 2025 deadline [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Petco made false and misleading statements regarding the sustainability of its pandemic-related business model and the strength of its product strategy [5]. - It is claimed that the defendants downplayed the severity of issues affecting Petco's business and overstated its ability to achieve sustainable growth, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vestis Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's growth potential and business performance [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $75,000 in Vestis between May 2, 2024, and May 6, 2025, to contact them for legal options [1]. - A federal securities class action has been filed against Vestis, with a deadline of August 8, 2025, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Financial Performance and Stock Impact - On May 7, 2025, Vestis announced disappointing financial results for Q2 2025, withdrawing its revenue and growth guidance for the full fiscal year and providing lower-than-expected guidance for Q3 2025 [5]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating challenges in customer retention and growth [5]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 11, 2025 [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities between September 17, 2024, and May 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding the effectiveness and safety of RP-A501, which was overstated [5]. - Specific claims include that RP-A501 was less effective than represented, and that changes to its clinical trial protocol increased the risk of Serious Adverse Events [5].

Core Viewpoint - The Rosen Law Firm is reminding purchasers of Reckitt Benckiser Group PLC's American Depositary Shares (ADSs) of a class action lawsuit with a lead plaintiff deadline of August 4, 2025, for those who bought shares between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Class Action Details - Investors who purchased Reckitt ADSs during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the August 4, 2025 deadline [2][4]. - The lawsuit alleges that Reckitt failed to warn investors about the increased risk of necrotizing enterocolitis (NEC) in preterm infants due to its cow's milk-based formula, Enfamil, which misled investors regarding the company's business prospects [4]. Group 2: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [3]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Centene Corporation due to misleading statements regarding the company's enrollment and morbidity rates, which led to a significant decline in stock price following the withdrawal of 2025 guidance [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Centene between December 12, 2024, and June 30, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Centene, with a deadline of September 8, 2025, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [6]. Group 2: Company Performance and Stock Impact - Centene's stock price fell dramatically from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [5]. - The company announced a reduction in its previously issued guidance to approximately $1.8 billion, with an adjusted diluted EPS of $2.75, following a disappointing analysis of its market growth [4]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].